metronidazole has been researched along with Hematologic Malignancies in 9 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 9.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| " difficile infection after therapy with metronidazole, vancomycin, or combination therapy exclusively in patients with hematologic malignancies, including those undergoing hematopoietic stem cell transplant for a hematologic condition." | 7.80 | A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. ( Bhatt, V; Parmar, SR; Schuster, M; Yang, J; Zhang, Q, 2014) |
| "In a single-center open-label prospective study, a total of 134 marrow transplant recipients with hematologic malignancies were randomly assigned to a bacterial decontamination medication using metronidazole and ciprofloxacin (n = 68) or ciprofloxacin alone (n = 66) during 5 weeks posttransplant." | 5.09 | Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and ( Beelen, DW; Elmaagacli, A; Hirche, H; Müller, KD; Schaefer, UW, 1999) |
| " difficile infection after therapy with metronidazole, vancomycin, or combination therapy exclusively in patients with hematologic malignancies, including those undergoing hematopoietic stem cell transplant for a hematologic condition." | 3.80 | A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies. ( Bhatt, V; Parmar, SR; Schuster, M; Yang, J; Zhang, Q, 2014) |
| "Adults with hematological malignancies are at high-risk of Clostridium difficile infection (CDI), but no guidelines for CDI treatment are available in this population." | 1.46 | Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable? ( Boyle, E; Galperine, T; Guery, B; Héquette-Ruz, R; Herbaux, C; Robin, C, 2017) |
| "Metronidazole was the primary treatment for 91 of 94 patients, 7 of 8 cases refractory to metronidazole had no response to vancomycin, and none was due to NAP1/027." | 1.40 | Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. ( Chung, D; Huang, YT; Jakubowski, AA; Kaltsas, A; Kamboj, M; Papanicolaou, G; Sepkowitz, K; Sheahan, A; Sun, J; Wu, S; Xiao, K, 2014) |
| "Diarrhea is a common complication of high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT)." | 1.31 | Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. ( Gordon, L; Mehta, J; Singhal, S; Tallman, M; Tomblyn, M; Williams, S; Winter, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robin, C | 1 |
| Héquette-Ruz, R | 1 |
| Guery, B | 1 |
| Boyle, E | 1 |
| Herbaux, C | 1 |
| Galperine, T | 1 |
| Martín Rizo, L | 1 |
| Malpartida Flores, M | 1 |
| Fernández Lisón, LC | 1 |
| Parmar, SR | 1 |
| Bhatt, V | 1 |
| Yang, J | 1 |
| Zhang, Q | 1 |
| Schuster, M | 1 |
| Kamboj, M | 1 |
| Xiao, K | 1 |
| Kaltsas, A | 1 |
| Huang, YT | 1 |
| Sun, J | 1 |
| Chung, D | 1 |
| Wu, S | 1 |
| Sheahan, A | 1 |
| Sepkowitz, K | 1 |
| Jakubowski, AA | 1 |
| Papanicolaou, G | 1 |
| Stewart, DB | 1 |
| Yacoub, E | 1 |
| Zhu, J | 1 |
| Tomblyn, M | 1 |
| Gordon, L | 1 |
| Singhal, S | 1 |
| Tallman, M | 1 |
| Williams, S | 1 |
| Winter, J | 1 |
| Mehta, J | 1 |
| Beelen, DW | 2 |
| Elmaagacli, A | 2 |
| Müller, KD | 2 |
| Hirche, H | 1 |
| Schaefer, UW | 2 |
| Trenschel, R | 1 |
| Peceny, R | 1 |
| Runde, V | 1 |
| Dermoumi, H | 1 |
| Heintschel von Heinegg, E | 1 |
| Gorschlüter, M | 1 |
| Glasmacher, A | 1 |
| Hahn, C | 1 |
| Schakowski, F | 1 |
| Ziske, C | 1 |
| Molitor, E | 1 |
| Marklein, G | 1 |
| Sauerbruch, T | 1 |
| Schmidt-Wolf, IG | 1 |
2 trials available for metronidazole and Hematologic Malignancies
| Article | Year |
|---|---|
Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bone Marrow Transplantation; Ciprofloxacin; Drug Therapy, | 1999 |
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; | 2000 |
7 other studies available for metronidazole and Hematologic Malignancies
| Article | Year |
|---|---|
Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
Topics: Adult; Clostridioides difficile; Clostridium Infections; Cross Infection; Disease Management; Female | 2017 |
Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Colonic Neoplasms; Diarrhea | 2019 |
A retrospective review of metronidazole and vancomycin in the management of Clostridium difficile infection in patients with hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Endpoint Determinat | 2014 |
Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Clostridioides difficile; C | 2014 |
Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients.
Topics: Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Antineoplastic Agents; Chi-Square Distribu | 2012 |
Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Disease Manageme | 2002 |
Clostridium difficile infection in patients with neutropenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Agents; Cross Infe | 2001 |